ACRP-CP Practice Test Questions Updated 127 Questions [Q36-Q56]

ACRP-CP Practice Test Questions Updated 127 Questions

ACRP ACRP-CP Dumps - Secret To Pass in First Attempt

NEW QUESTION # 36
Who is responsible for the ongoing safety evaluation of the IP?

• A. Sponsor
• B. Regulatory agency
• C. PI
• D. IRB/IEC

Answer: A

Explanation:
The sponsor is primarily responsible for the ongoing safety evaluation of the investigational product (IP) throughout the clinical trial. This responsibility includes monitoring adverse events, reporting serious adverse events (SAEs) to regulatory authorities, and updating the Investigator's Brochure (IB) with relevant safety data.
According to GCP guidelines, the sponsor must continuously evaluate safety data and report findings to regulatory bodies as necessary.
"The sponsor is responsible for the continuous safety monitoring of the investigational product and for ensuring that new safety information is communicated to investigators and regulators." Objectives:
* Ensure participant safety throughout the study.
* Maintain accurate and timely reporting of safety data.

NEW QUESTION # 37
In preparation for an upcoming site audit, whose responsibility is it to ensure study-related functions were conducted by qualified personnel?

• A. CRC
• B. CRA
• C. Investigator
• D. Sponsor

Answer: C

Explanation:
The Principal Investigator (PI) holds ultimate responsibility for ensuring that all study-related functions are conducted by qualified and trained personnel. The PI must verify that staff have the necessary qualifications and training to perform their assigned tasks as outlined in the protocol. This responsibility is crucial for maintaining compliance with GCP and ensuring data integrity.
According to GCP guidelines, the PI must ensure that all staff assisting with the trial are adequately trained and qualified for their roles.
"The investigator is responsible for ensuring that all persons assisting with the trial are qualified by education, training, and experience to perform their respective tasks." Objectives:
* Maintain compliance with GCP requirements.
* Ensure qualified personnel conduct study tasks.

NEW QUESTION # 38
What would a sponsor use to implement and maintain quality in a study?

• A. Standard operating procedures
• B. Protocol signature pages
• C. Clinical trial agreement
• D. Statistical analysis plan

Answer: A

Explanation:
Standard Operating Procedures (SOPs) are essential for implementing and maintaining quality in a clinical study. SOPs outline the standardized methods for conducting study-related tasks, ensuring consistency, compliance, and quality across all trial sites. They are critical for training personnel, guiding the conduct of study activities, and maintaining protocol adherence.
GCP guidelines state that sponsors must develop and maintain SOPs to ensure the quality and consistency of clinical trial processes.
"The sponsor should establish SOPs to maintain the quality of clinical trials, covering all aspects of trial conduct, data handling, and safety management." Objectives:
* Ensure consistent and high-quality trial conduct.
* Standardize procedures across trial sites.

NEW QUESTION # 39
The primary purpose for IRB/IEC approval of posters, fliers, social media posts, and promotional items is to:

• A. Review the content for ethically or morally sensitive issues.
• B. Safeguard the rights, safety, and well-being of all potential subjects.
• C. Confirm subjects receive the appropriate reimbursement.
• D. Assure the ads do not impinge on confidentiality agreements.

Answer: B

Explanation:
The IRB/IEC's primary responsibility when reviewing recruitment materials such as posters, fliers, social media posts, and promotional items is to ensure that these materials safeguard the rights, safety, and well- being of potential participants. This includes ensuring that the information is presented ethically, clearly, and without coercion, maintaining compliance with ethical guidelines.
GCP guidelines require that any materials used for recruitment be reviewed to ensure they do not mislead participants and that they respect their rights and well-being.
"IRB/IEC review of recruitment materials ensures that they protect participants' rights and well-being and that the content is ethically appropriate." Objectives:
* Maintain ethical standards in recruitment.
* Protect potential participants from misleading or coercive information.

NEW QUESTION # 40
The IRB/IEC has decided to not approve a clinical trial. Who must they notify in writing?

• A. Regulatory Agency
• B. CRC
• C. Sponsor
• D. PI

Answer: D

Explanation:
When the IRB/IEC decides not to approve a clinical trial, they must notify the Principal Investigator (PI) in writing. This communication ensures that the PI is formally informed of the decision and cantake appropriate actions, such as revising the protocol or addressing the reasons for disapproval.
According to GCP guidelines, the IRB/IEC must communicate any decision regarding the approval status of a study directly to the PI, as the PI is responsible for the conduct of the trial.
"The IRB/IEC should promptly notify the investigator in writing of its decision to approve or disapprove the proposed research activity." Objectives:
* Maintain clear communication between the IRB/IEC and the investigator.
* Ensure timely notification of decisions affecting the study.

NEW QUESTION # 41
A sponsor wants a new clinical trial to be reviewed at regular intervals for progress, safety, and endpoint evaluation, and make recommendations to continue, modify, or stop the trial. How should they proceed?

• A. Develop a monitoring plan
• B. Draft a CAPA plan
• C. Establish a DSMB/IDMC
• D. Conduct routine investigators' meetings

Answer: C

Explanation:
A Data Safety Monitoring Board (DSMB) or Independent Data Monitoring Committee (IDMC) is established to review ongoing trial data at regular intervals. The DSMB evaluates safety, progress, and efficacy endpoints and makes recommendations to continue, modify, or terminate the study based on interim data. This independent oversight helps ensure participant safety and data integrity throughout the trial.
GCP guidelines recommend forming a DSMB for studies that involve high risks or long durations, ensuring continuous safety monitoring.
"The DSMB is responsible for the periodic review of accumulating data and providing recommendations regarding trial continuation, modification, or termination." Objectives:
* Ensure ongoing safety evaluation.
* Facilitate objective decisions on trial continuation.

NEW QUESTION # 42
When assessing the monitoring needs for a study, sponsors should:

• A. Ensure monitoring visits are conducted at periodic intervals with a minimum of monthly monitoring visits.
• B. Use central monitoring instead of conducting physical monitoring visits at sites.
• C. Ensure monitors have the scientific and/or clinical knowledge needed to monitor the trial adequately.
• D. Permit PIs to select a monitor for their site as long as they are independent of the PI.

Answer: C

Explanation:
Sponsors must ensure that monitors are adequately qualified, possessing the necessary scientific and clinical knowledge to effectively oversee the trial. This ensures that monitors can accurately assess protocol compliance, data integrity, and participant safety. The quality of monitoring directly impacts the credibility of the trial outcomes.
GCP guidelines specify that monitors must be adequately trained and knowledgeable about the trial protocol, investigational product (IP), and clinical research standards.
"The sponsor must ensure that monitors have appropriate qualifications and training to conduct effective trial monitoring." Objectives:
* Maintain data integrity through skilled monitoring.
* Ensure patient safety and protocol compliance.

NEW QUESTION # 43
A study sponsor approaches a facility about participating in their research study. The study sponsor requires use of social media as its sole method of recruitment. The site knows their institutional IRB/IEC does not approve of social media recruiting. How should the site respond?

• A. Recruit for the study without use of social media.
• B. Use a central IRB/IEC.
• C. Decline the study.
• D. Rely on the sponsor to notify the IRB/IEC.

Answer: C

Explanation:
If the IRB/IEC has a policy that does not permit social media recruiting, the site must adhere to these regulations. Proceeding with a method not approved by the IRB/IEC would violate compliance requirements, so declining the study is the correct course of action.
The answer aligns with IRB/IEC regulations that prioritize ethical and compliant recruitment methods.
"Sites must follow the recruitment methods approved by their IRB/IEC to maintain compliance and ethical standards." Objectives:
* Adhering to ethical recruitment practices.
* Maintaining compliance with IRB/IEC policies.

NEW QUESTION # 44
In order to conduct open-label, parallel group clinical trials according to sound scientific principles, which of the following design elements should be included?

• A. Placebo-controlled
• B. Randomization
• C. Privacy controls
• D. Blinding

Answer: B

Explanation:
Randomization is a key element in open-label, parallel group clinical trials to reduce selection bias and ensure that participant allocation is not influenced by investigators. Despite the absence of blinding in open-label studies, randomization maintains the validity and reliability of the results by evenly distributing confounding factors between groups.
GCP guidelines recommend randomization as a core element in clinical trial design to ensure unbiased allocation of participants.
"Randomization in parallel group trials helps minimize selection bias and ensures the comparability of intervention groups." Objectives:
* Maintain scientific rigor through randomization.
* Minimize selection bias in clinical studies.

NEW QUESTION # 45
A clinical trial is conducted to test the effect of an investigational drug on cholesterol levels. Statistical analysis will be performed to:

• A. Fail to reject the null hypothesis that the drug has an effect on cholesterol levels.
• B. Reject the alternative hypothesis that the drug has no effect on cholesterol levels.
• C. Fail to reject the alternative hypothesis that the drug has an effect on cholesterol levels.
• D. Reject the null hypothesis that the drug has no effect on cholesterol levels.

Answer: D

Explanation:
The purpose of statistical analysis in a clinical trial is to evaluate whether the data supports rejecting the null hypothesis, which typically states that there is no effect or difference. If the analysis finds a statistically significant result, the null hypothesis is rejected, indicating that the investigational drug has an effect on cholesterol levels.
The answer follows statistical principles in clinical trials, where the null hypothesis is rejected if evidence shows a significant difference or effect.
"In hypothesis testing, rejecting the null hypothesis indicates that the treatment effect is statistically significant." Objectives:
* Understand hypothesis testing in clinical research.
* Interpret statistical outcomes accurately.

NEW QUESTION # 46
Which of the following is a conflict of interest for a PI conducting a study?

• A. A PI who receives payment for the study
• B. A PI that votes on the IRB/IEC approval of the protocol
• C. A PI who is a key opinion leader, writes the protocol
• D. A PI that presents at an investigator meeting

Answer: B

Explanation:
A Principal Investigator (PI) who is involved in voting on the IRB/IEC approval of their own protocol is considered to have a conflict of interest. The IRB/IEC must be independent and impartial when reviewing research proposals. Allowing the PI to vote on their own study compromises the ethical review process. To maintain unbiased decision-making, PIs must recuse themselves from such votes.
GCP guidelines emphasize the importance of avoiding conflicts of interest in the IRB/IEC decision-making process to maintain objectivity and ethical standards.
"A PI should not participate in voting or decision-making processes regarding the approval of their own study to avoid conflicts of interest." Objectives:
* Maintain impartiality in ethical review.
* Prevent conflicts of interest during IRB/IEC processes.

NEW QUESTION # 47
Who determines the age of assent for pediatric studies?

• A. IRB/IEC
• B. Parent
• C. Sponsor
• D. PI

Answer: A

Explanation:
The IRB/IEC determines the age at which a child is considered capable of providing assent for participation in a clinical trial. This decision is based on local regulations, cultural considerations, and the child's ability to understand the trial's risks and benefits. The age of assent may vary between jurisdictions and is subject to ethical considerations specific to pediatric research.
GCP guidelines emphasize that the IRB/IEC is responsible for setting the criteria for obtaining assent from minors based on ethical and regulatory frameworks.
"The IRB/IEC is responsible for determining the age and circumstances under which pediatric assent is required, considering the child's comprehension level." Objectives:
* Ensure appropriate ethical practices in pediatric research.
* Align with local regulatory requirements for assent.

NEW QUESTION # 48
A double-blind randomized Phase III trial seeks to recruit 500 subjects in 2 years. At the end of the first year,
150 subjects have been enrolled. Monitoring reports from the first year note 50% of subjects screened were screen failures due to exclusionary lab values. What action should the sponsor take?

• A. Re-train investigators on recruitment obligations.
• B. Evaluate the screen failures to determine if the protocol needs revision.
• C. Reduce the target sample size based on feedback from the sites.
• D. Allocate additional monitoring resources to the trial.

Answer: B

Explanation:
The high rate of screen failures indicates that the inclusion/exclusion criteria may be too stringent or not appropriately defined. The sponsor should evaluate the reasons for these failures and determine whether the protocol needs adjustment. Revising the criteria may increase recruitment efficiency without compromising the scientific validity of the study.
GCP guidelines advise reviewing and possibly revising protocols when screen failure rates are significantly high to ensure feasible recruitment.
"If a high number of screen failures occurs, the sponsor should evaluate the inclusion/exclusion criteria and consider protocol revisions." Objectives:
* Improve recruitment efficiency.
* Adapt protocol criteria to real-world conditions.

NEW QUESTION # 49
Which of the following should be considered when implementing a risk-based monitoring plan?

• A. On-site monitoring frequency may change depending on the quality of the data.
• B. Centralized monitoring must be incorporated in any trials.
• C. Monitoring schedule must be pre-defined in the monitoring plan.
• D. 100% source document review is mandatory.

Answer: A

Explanation:
Risk-based monitoring focuses on adapting the frequency and intensity of on-site visits based on data quality and site performance. If the data is consistently accurate and reliable, the monitoring frequency may be reduced. Conversely, if issues are identified, more frequent monitoring may be necessary.
GCP guidelines emphasize a flexible approach to monitoring, allowing adjustments based on the risk profile and quality of data collected.
"Risk-based monitoring involves adapting the frequency of on-site visits according to the quality of the data and the site's compliance level." Objectives:
* Implement a dynamic monitoring strategy.
* Enhance efficiency while maintaining data integrity.

NEW QUESTION # 50
The coding system for a double-blind clinical trial is accessible by the:

• A. Sponsor
• B. Regulatory authority
• C. PI
• D. IRB/IEC

Answer: A

Explanation:
The sponsor is typically responsible for maintaining the code that links the treatment assignment to participants in a double-blind clinical trial. The code is securely maintained and is only accessible in cases where unblinding is necessary for safety reasons. This process helps to preserve the integrity of the study while allowing for emergency unblinding if needed.
GCP guidelines state that the sponsor should maintain the blind unless unblinding is necessary due to safety concerns or regulatory requirements.
"The sponsor maintains the randomization code and ensures that unblinding occurs only when necessary, to protect the study's integrity." Objectives:
* Maintain the integrity of double-blind trials.
* Allow controlled access to randomization codes.

NEW QUESTION # 51
All site financial matters pertaining to a trial are listed in what document?

• A. Signed contract
• B. Protocol
• C. Informed consent form
• D. Financial disclosure

Answer: A

Explanation:
All financial agreements, including compensation, budgeting, and payment terms related to the conduct of a clinical trial, are documented in the signed contract between the sponsor and the site. This contract outlines the financial responsibilities and ensures transparency and compliance.
GCP guidelines stipulate that financial matters related to the conduct of a trial are to be formally documented in contractual agreements.
"The financial aspects of a clinical trial must be outlined in the signed agreement between the sponsor and the site, ensuring clear understanding of compensation and obligations." Objectives:
* Ensure financial transparency and accountability.
* Maintain compliance with contractual obligations.

NEW QUESTION # 52
Centralized monitoring can:

• A. Identify IP accountability and storage issues.
• B. Enable appropriate stratification of subject enrollment.
• C. Confirm why sites are deviating from the protocol.
• D. Indicate the need to send monitors to perform onsite visits.

Answer: D

Explanation:
Centralized monitoring involves the remote evaluation of data trends, outliers, and inconsistencies across sites. If significant issues are identified through centralized monitoring, it may prompt the need for targeted on-site visits to investigate and resolve the identified issues. This approach optimizes resource utilization and focuses on potential problem areas.
GCP guidelines support the use of centralized monitoring to identify risks that warrant on-site monitoring, promoting efficient and targeted oversight.
"Centralized monitoring can identify data patterns or anomalies that indicate the need for an on-site visit to verify and address the issue." Objectives:
* Enhance monitoring efficiency through data-driven decisions.
* Prioritize on-site visits based on identified risks.

NEW QUESTION # 53
A PI on a study is a regular member of the IRB/IEC. Which of the following statements is TRUE regarding their participation in the IRB/IEC discussion and deliberation?

• A. They cannot be the PI on the clinical study due to conflict of interest.
• B. They must recuse themselves from the meeting given their dual roles as IRB/IEC member and PI.
• C. They can attend the meeting and can vote/provide opinion on whether to approve the study.
• D. They can attend the meeting, but should not vote/provide opinion on whether to approve the study.

Answer: B

Explanation:
If a PI is also a member of the IRB/IEC, they must recuse themselves from the meeting when their own study is being reviewed to avoid conflicts of interest. This practice preserves the objectivity and impartiality of the IRB/IEC's decisions.
The answer is verified based on IRB/IEC operational guidelines, which mandate that members with potential conflicts recuse themselves from discussions and voting.
"To maintain objectivity, IRB/IEC members who have a conflict of interest related to a study must recuse themselves from the review and decision-making process." Objectives:
* Maintain impartiality in IRB/IEC decisions
* Prevent conflicts of interest in clinical trial approval

NEW QUESTION # 54
Who determines what criteria and procedures should be followed if a subject discontinues/withdraws their consent?

• A. Sponsor
• B. Subject
• C. CRO
• D. PI

Answer: A

Explanation:
The sponsor is responsible for defining the criteria and procedures for subject withdrawal or discontinuation of consent. This includes specifying how data already collected will be handled and whether any follow-up is required. The procedures must be clearly outlined in the study protocol and communicated to the research team.
This answer follows GCP guidelines, which state that the sponsor must ensure that procedures for subject withdrawal are clearly defined and documented.
"The sponsor is responsible for defining procedures to be followed if a subject discontinues participation or withdraws consent, including handling of data collected prior to withdrawal." Objectives:
* Ensure transparent procedures for participant withdrawal.
* Maintain data integrity while respecting participant autonomy.

NEW QUESTION # 55
While consenting a potential subject, a coordinator discovered the subject could not read. Under what conditions can this potential subject be enrolled?

• A. Have the Principal Investigator consent the person.
• B. Get an impartial witness involved in consenting this person.
• C. There are no circumstances under which this person can be enrolled.
• D. Locate a translator and have them work with the person.

Answer: B

Explanation:
When a participant cannot read, an impartial witness must be present during the consent process. The witness ensures that the information is accurately presented and that the subject's consent is truly informed. The witness must sign the consent form to attest that the subject understands the information.
GCP guidelines require the use of an impartial witness during the informed consent process for individuals who are illiterate or visually impaired.
"Informed consent must involve an impartial witness when the subject cannot read, ensuring the consent process is conducted ethically." Objectives:
* Maintain ethical standards during consent.
* Protect the rights of participants with literacy challenges.

NEW QUESTION # 56
......

ACRP ACRP-CP Exam Dumps [2025] Practice Valid Exam Dumps Question: https://www.passcollection.com/ACRP-CP_real-exams.html

ACRP-CP Dumps - Grab Out For [NEW-2025] ACRP Exam: https://drive.google.com/open?id=1rHumGGqSlO1F8ESZxmveyeZ1fL6kNu-i